Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev next > | last >>
presentations: 1 to 25 of 11998
page: of 480 records per page:
Therapeutic modulation of E3 ubiquitin ligase activity
Benjamin L. Ebert
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 26, 2019 5:00 PM-7:00 PM
Navigating gene-gene and drug-gene interaction landscapes underpinning the DNA damage response
Daniel Durocher
Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 8:00 AM-9:45 AM
Background and use of circulating tumor-derived DNA and circulating tumor cells as biomarkers
Martijn Lolkema
Erasmus MC, Rotterdam, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 10:00 AM-11:45 AM
The KRASG12C inhibitor, MRTX849, provides insight toward therapeutic susceptibility of KRAS mutant cancers
James G Christensen
Mirati Therapeutics, San Diego, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRASG12C inhibitor, in advanced solid tumors
Pasi A Jänne
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 28, 2019 4:15 PM-6:00 PM
The dark side of immunotherapy
Emiliano Calvo
Start Madrid, Madrid, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 8:00 AM-9:45 AM
Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman
The Institute of Cancer Research, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 10:00 AM-11:45 AM
Early lessons from initial acquired resistance to TRK inhibitors
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
From big data to smart data: Overcoming biomedical reductionism
Sean Khozin
U.S. Food & Drug Administration, Silver Spring, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 30, 2019 8:00 AM-9:45 AM
Identifying novel immunotherapy strategies using human samples and pre-clinical models
Jennifer L Guerriero
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 30, 2019 10:00 AM-12:00 PM
Successes and failures of targeted drug development in adult and pediatric sarcomas
Jaap Verweij
Erasmus University Medical Center, Rotterdam, Netherlands
from 2019 Molecular Targets and Cancer Therapeutics conference on October 26, 2019 3:00 PM-4:45 PM
Successes and failures of targeted drug development in pediatric tumors
Elizabeth Fox
Children’s Hospital of Pennsylvania, Philadelphia, PA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 26, 2019 3:00 PM-4:45 PM
Targeted therapy with protein kinase inhibitors: Lessons learned from the last 20 years
Michael C Heinrich
Oregon Health and Science University, Portland, OR, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 26, 2019 3:00 PM-4:45 PM
Dissecting antitumor immune response in ovarian cancer
George Coukos
University of Lausanne, Lausanne, Switzerland, Lausanne, Switzerland
from 2019 Molecular Targets and Cancer Therapeutics conference on October 26, 2019 5:00 PM-7:00 PM
New CAR T cells on the horizon
Marcela V Maus
Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
New targets and technologies for CAR-T
Michael Hudecek
University Hospital Wurzburg, Wurzburg, Germany
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
Engineering CAR T Cells to Overcome Resistance
Crystal L Mackall
Stanford University School of Medicine, Stanford, California, Stanford, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 8:00 AM-9:45 AM
Targeted Protein Degradation as a new Approach to Cancer Drugs
Nathanael S Gray
Dana-Farber Cancer Institute, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
Exploiting E3 ligases for target validation and drug discovery: What have we learnt so far?
Rajesh Chopra
The Institute of Cancer Research, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
The zinc-finger degrome
Nicolas H. Thoma
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 10:00 AM-11:45 AM
A phase I study targeting the APE1/Ref-1 DNA repair-redox signaling protein with the APX3330 inhibitor
Mark R. Kelley
Indiana University School of Medicine, Indianapolis, IN, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
Alison M Schram
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion
Rebecca S Heist
Massachusetts General Hospital, Boston, MA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 11:50 AM-12:20 PM
CAR-T and directed T-cell therapy: Where are we right now?
Victor Moreno
START Madrid, Hospital Fundación Jiménez Díaz, Madrid, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
Smita Chandran
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 27, 2019 4:15 PM-6:00 PM
<< first | < prev next > | last >>
presentations: 1 to 25 of 11998
page: of 480 records per page: